FY26 Annual Report: Profit Dips Amid Heavy Capex, CDMO Shines
Aarti Pharmalabs Limited · AARTIPHARM · NSE ·
• <b>Financials (FY26):</b> Revenue stood at ₹1,819 Cr (↓14% YoY) and Profit After Tax (PAT) at ₹174 Cr (↓36% YoY), impacted by a challenging API market and accounting changes for a joint venture. • <b>Dividend Declared:</b> A total dividend of ₹3.50 per share has been declared f…